SuperGen Granted FDA Approval of Paclitaxel ANDA

DUBLIN, Calif., Nov 15, 2004 /PRNewswire-FirstCall via COMTEX/ -- SuperGen, Inc. (Nasdaq: SUPG) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Paclitaxel Injection, 6 mg/mL, packaged in 30 mg/5 mL and 100 mg/16.7 mL multiple-dose vials.

Paclitaxel belongs to the group of medicines called antineoplastics. The drug is equivalent to Bristol-Myers Squibb's Taxol® Injection; an antitumor agent that has become one of the most widely used anti-cancer products.

Paclitaxel Injection's approved indication is identical to Taxol® and is indicated as treatment for a variety of cancers.

"FDA approval of our ANDA to market Paclitaxel in the U.S. is a significant accomplishment for SuperGen," stated James Manuso, Ph.D., President and Chief Executive Officer. "We are currently in discussions with several U.S. multi-source generic manufacturers specializing in oncology and hope to complete a marketing and distribution licensing agreement during the first half of 2005."

About SuperGen

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen's product portfolio includes Nipent® (pentostatin for injection); Mitomycin (generic brand of Mitomycin®); and SurfaceSafe® cleaner. For more information about SuperGen, please visit http://www.supergen.com.

This press release contains "forward-looking" statements within the meaning of section 21A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. Such forward-looking statements include statements regarding expectations about completing a marketing and distribution license agreement for Paclitaxel. References made to the discussion of the risk factors are detailed in the Company's filing with the Securities and Exchange Commission including the report on Form 10-Q for the quarter ended September 30, 2004. These forward-looking statements are made only as of the date hereof, and the company disclaims any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Timothy L. Enns
SuperGen, Inc.
Tel: 1 (925) 560-0100 x111
tenns@supergen.com

Sharon Weinstein
Euro RSCG Life NRP
Tel: 1 (212) 845-4271
sharon.weinstein@eurorscg.com

SOURCE SuperGen, Inc.

http://www.supergen.com